Home > Research > Publications & Outputs > Effect of resveratrol on non-alcoholic fatty li...

Research

Links

Text available via DOI:

Keywords

View graph of relations

Effect of resveratrol on non-alcoholic fatty liver disease

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Effect of resveratrol on non-alcoholic fatty liver disease. / Theodotou, Marios; Fokianos, Konstantinos; Moniatis, Demetris et al.
In: Experimental and Therapeutic Medicine, Vol. 18, No. 1, 01.07.2019, p. 559-565.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Theodotou, M, Fokianos, K, Moniatis, D, Kadlenic, R, Chrysikou, A, Aristotelous, A, Mouzouridou, A, Diakides, J & Stavrou, E 2019, 'Effect of resveratrol on non-alcoholic fatty liver disease', Experimental and Therapeutic Medicine, vol. 18, no. 1, pp. 559-565. https://doi.org/10.3892/etm.2019.7607

APA

Theodotou, M., Fokianos, K., Moniatis, D., Kadlenic, R., Chrysikou, A., Aristotelous, A., Mouzouridou, A., Diakides, J., & Stavrou, E. (2019). Effect of resveratrol on non-alcoholic fatty liver disease. Experimental and Therapeutic Medicine, 18(1), 559-565. https://doi.org/10.3892/etm.2019.7607

Vancouver

Theodotou M, Fokianos K, Moniatis D, Kadlenic R, Chrysikou A, Aristotelous A et al. Effect of resveratrol on non-alcoholic fatty liver disease. Experimental and Therapeutic Medicine. 2019 Jul 1;18(1):559-565. Epub 2019 May 23. doi: 10.3892/etm.2019.7607

Author

Theodotou, Marios ; Fokianos, Konstantinos ; Moniatis, Demetris et al. / Effect of resveratrol on non-alcoholic fatty liver disease. In: Experimental and Therapeutic Medicine. 2019 ; Vol. 18, No. 1. pp. 559-565.

Bibtex

@article{9eba8bdc0418447db900a1ff0fc5ab2a,
title = "Effect of resveratrol on non-alcoholic fatty liver disease",
abstract = "The aim of the present study was to investigate the effect of a micronized formulation of trans-resveratrol in humans with non-alcoholic fatty liver disease (NAFLD). Trans-Resveratrol has been used in the form of micronized formulation, which is better absorbed, has strong antioxidants effects, is more effective than plain resveratrol formulations and is circulated on the market as a food supplement.Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a stilbenoid and a phytoalexin produced by several plants. NAFLD is an increasing clinical problem involving the liver for which effective treatments are required. The present study was basedon two patient groups. The study, which commenced on April 2013 and finished on April 2015, included 44 patients, aged 29-70 years, with an average weight of 84.6 kg (n=22 per group; 28 men and 16 women) who were randomly assigned to groups and given 50 mg Evelor capsule (n=22) and 200 mg Evelor H tablet (n=22) correspondingly on a daily basis. The patients were followed up for 6 months. Quantity fat measurements, with ultrasound on the liver and kidney, were carried out. There was an initial measurement (time 1) and one after six months (time 2). The study results showed the effects of Trans-resveratrol micronized formulation in reducing the liver fat, as well as decreasing hepatic enzymes, serum glutamate pyruvic transaminase (SGPT) and gamma-glutamyl transpeptidase (g-GT) and insulin resistance. At the end of the study, the statistical analysis showed a statistically significant reduction on the liver fat. These data demonstrate that use of Trans-resveratrol micronized formulation improves features of NAFLD, and prevents liver damage. Thus, Trans-resveratrolmicronized formulation can be a new treatment method for NAFLD.",
keywords = "liver, resveratrol, non-alcoholic fatty liver disease, hepatic enzymes, liver value",
author = "Marios Theodotou and Konstantinos Fokianos and Demetris Moniatis and Rudolf Kadlenic and Asimina Chrysikou and Andrea Aristotelous and Alexia Mouzouridou and John Diakides and Eliza Stavrou",
year = "2019",
month = jul,
day = "1",
doi = "10.3892/etm.2019.7607",
language = "English",
volume = "18",
pages = "559--565",
journal = "Experimental and Therapeutic Medicine",
issn = "1792-0981",
publisher = "Spandidos Publications",
number = "1",

}

RIS

TY - JOUR

T1 - Effect of resveratrol on non-alcoholic fatty liver disease

AU - Theodotou, Marios

AU - Fokianos, Konstantinos

AU - Moniatis, Demetris

AU - Kadlenic, Rudolf

AU - Chrysikou, Asimina

AU - Aristotelous, Andrea

AU - Mouzouridou, Alexia

AU - Diakides, John

AU - Stavrou, Eliza

PY - 2019/7/1

Y1 - 2019/7/1

N2 - The aim of the present study was to investigate the effect of a micronized formulation of trans-resveratrol in humans with non-alcoholic fatty liver disease (NAFLD). Trans-Resveratrol has been used in the form of micronized formulation, which is better absorbed, has strong antioxidants effects, is more effective than plain resveratrol formulations and is circulated on the market as a food supplement.Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a stilbenoid and a phytoalexin produced by several plants. NAFLD is an increasing clinical problem involving the liver for which effective treatments are required. The present study was basedon two patient groups. The study, which commenced on April 2013 and finished on April 2015, included 44 patients, aged 29-70 years, with an average weight of 84.6 kg (n=22 per group; 28 men and 16 women) who were randomly assigned to groups and given 50 mg Evelor capsule (n=22) and 200 mg Evelor H tablet (n=22) correspondingly on a daily basis. The patients were followed up for 6 months. Quantity fat measurements, with ultrasound on the liver and kidney, were carried out. There was an initial measurement (time 1) and one after six months (time 2). The study results showed the effects of Trans-resveratrol micronized formulation in reducing the liver fat, as well as decreasing hepatic enzymes, serum glutamate pyruvic transaminase (SGPT) and gamma-glutamyl transpeptidase (g-GT) and insulin resistance. At the end of the study, the statistical analysis showed a statistically significant reduction on the liver fat. These data demonstrate that use of Trans-resveratrol micronized formulation improves features of NAFLD, and prevents liver damage. Thus, Trans-resveratrolmicronized formulation can be a new treatment method for NAFLD.

AB - The aim of the present study was to investigate the effect of a micronized formulation of trans-resveratrol in humans with non-alcoholic fatty liver disease (NAFLD). Trans-Resveratrol has been used in the form of micronized formulation, which is better absorbed, has strong antioxidants effects, is more effective than plain resveratrol formulations and is circulated on the market as a food supplement.Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a stilbenoid and a phytoalexin produced by several plants. NAFLD is an increasing clinical problem involving the liver for which effective treatments are required. The present study was basedon two patient groups. The study, which commenced on April 2013 and finished on April 2015, included 44 patients, aged 29-70 years, with an average weight of 84.6 kg (n=22 per group; 28 men and 16 women) who were randomly assigned to groups and given 50 mg Evelor capsule (n=22) and 200 mg Evelor H tablet (n=22) correspondingly on a daily basis. The patients were followed up for 6 months. Quantity fat measurements, with ultrasound on the liver and kidney, were carried out. There was an initial measurement (time 1) and one after six months (time 2). The study results showed the effects of Trans-resveratrol micronized formulation in reducing the liver fat, as well as decreasing hepatic enzymes, serum glutamate pyruvic transaminase (SGPT) and gamma-glutamyl transpeptidase (g-GT) and insulin resistance. At the end of the study, the statistical analysis showed a statistically significant reduction on the liver fat. These data demonstrate that use of Trans-resveratrol micronized formulation improves features of NAFLD, and prevents liver damage. Thus, Trans-resveratrolmicronized formulation can be a new treatment method for NAFLD.

KW - liver

KW - resveratrol

KW - non-alcoholic fatty liver disease

KW - hepatic enzymes

KW - liver value

U2 - 10.3892/etm.2019.7607

DO - 10.3892/etm.2019.7607

M3 - Journal article

VL - 18

SP - 559

EP - 565

JO - Experimental and Therapeutic Medicine

JF - Experimental and Therapeutic Medicine

SN - 1792-0981

IS - 1

ER -